CLINICAL TRIALS PROFILE FOR PONATINIB HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for PONATINIB HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00660920 ↗ | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | Completed | Ariad Pharmaceuticals | Phase 1 | 2008-06-01 | The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies. |
| NCT01207440 ↗ | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | Completed | Ariad Pharmaceuticals | Phase 2 | 2010-09-30 | The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation. |
| NCT01424982 ↗ | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | Ariad Pharmaceuticals | Phase 2 | 2011-10-05 | This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia. |
| NCT01424982 ↗ | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | M.D. Anderson Cancer Center | Phase 2 | 2011-10-05 | This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia. |
| NCT01549548 ↗ | Compassionate Use Ponatinib | No longer available | Ariad Pharmaceuticals | 1969-12-31 | The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment. | |
| NCT01549548 ↗ | Compassionate Use Ponatinib | No longer available | OHSU Knight Cancer Institute | 1969-12-31 | The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment. | |
| NCT01570868 ↗ | Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | Terminated | Ariad Pharmaceuticals | Phase 2 | 2012-04-01 | The goal of this clinical research study is to learn if ponatinib can help to control Chronic Myeloid Leukemia (CML) in accelerated phase. The safety of this drug will also be studied. Ponatinib is designed to block the function of BCR-ABL, which is the abnormal protein responsible for causing leukemia in certain cells. Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in 4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that do not have other known risk factors for forming clots. If you develop a blood clot, you will need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the clot and restore blood flow. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PONATINIB HYDROCHLORIDE
Condition Name
Condition MeSH
| Condition MeSH for PONATINIB HYDROCHLORIDE | |
| Intervention | Trials |
| Leukemia | 45 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 33 |
| Leukemia, Myeloid | 32 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 30 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for PONATINIB HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for PONATINIB HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for PONATINIB HYDROCHLORIDE
Sponsor Name
